- Tytuł:
-
192MO DESTINY-Breast04 subgroup analyses of trastuzumab deruxtecan (T-DXd) vs treatment of physician’
s choice (TPC) in patients (pts) with human epidermal growth factor 2 (HER2)-low, estrogen-receptor (ER) expression immunohistochemistry (IHC) 0-10% metastatic breast cancer (mBC) - Autorzy:
- Źródło:
- In ESMO Open May 2023 8(1) Supplement 4
Czasopismo naukowe